Antagonists of iap-shps1 interaction

Abstract

Provided herein is technology relating to antagonists that inhibit, reduce, or minimize the interaction of integrin associated protein (IAP) with Src homology 2 (SH2) domain-containing protein tyrosine phosphatase substrate 1 (SHPS1) and particularly, but not exclusively, to compositions comprising such antagonists and methods of treatment comprising administering such antagonists.

That which is claimed is: 
     
         1 . A monoclonal antibody that specifically binds an epitope within amino acids 71-80 of the human IAP protein and is an antagonist of IAP to SHPS-1 binding. 
     
     
         2 . The antibody of  claim 1 , coupled to a detectable group. 
     
     
         3 . The antibody of  claim 1 , coupled to a therapeutic group. 
     
     
         4 . The antibody of  claim 1 , wherein the antibody does not disrupt IAP binding to a β 3  protein. 
     
     
         5 . A pharmaceutical formulation comprising the antibody of  claim 1  in a pharmaceutically acceptable carrier. 
     
     
         6 . The antibody of  claim 1 , wherein the antibody is selected from the group consisting of (a) the monoclonal antibody produced by hybridoma R569, and (b) a monoclonal antibody that competes for binding to the same epitope as the epitope bound by a monoclonal antibody produced by the hybridoma R569. 
     
     
         7 . The antibody of  claim 6 , coupled to a detectable group. 
     
     
         8 . The antibody of  claim 6 , coupled to a therapeutic group. 
     
     
         9 . A pharmaceutical formulation comprising the antibody of  claim 6  in a pharmaceutically acceptable carrier. 
     
     
         10 . A method of inhibiting IGF-1 actions in a subject in need thereof, comprising administering to the subject the antibody of  claim 1 . 
     
     
         11 . A method of inhibiting IGF-1 actions in a subject in need thereof, comprising administering to the subject the antibody of  claim 6 . 
     
     
         12 . A method of treating diabetic retinopathy in a subject, comprising administering to the subject an effective amount of the antibody of  claim 1 . 
     
     
         13 . A method of treating diabetic atherosclerosis in a subject, comprising administering to the subject an effective amount of the antibody of  claim 1 . 
     
     
         14 . A method of treating diabetic nephropathy in a subject, comprising administering to the subject an effective amount of the antibody of  claim 1 . 
     
     
         15 . A method of treating coronary artery disease in a subject, comprising administering to the subject an effective amount of the antibody of  claim 1 . 
     
     
         16 . A method of treating diabetic retinopathy in a subject, comprising administering to the subject an effective amount of the antibody of  claim 6 . 
     
     
         17 . A method of treating diabetic atherosclerosis in a subject, comprising administering to the subject an effective amount of the antibody of  claim 6 . 
     
     
         18 . A method of treating diabetic nephropathy in a subject, comprising administering to the subject an effective amount of the antibody of  claim 6 . 
     
     
         19 . A method of treating coronary artery disease in a subject, comprising administering to the subject an effective amount of the antibody of  claim 6 . 
     
     
         20 . The method of  claim 12 , wherein the antibody is administered by subcutaneous injection or intravenous infusion.